Myra Vision is a Campbell, California medical device company developing the Calibreye Titratable Glaucoma Therapy Surgical System - a next-generation aqueous shunt with adjustable outflow channels that let surgeons fine-tune intraocular pressure in glaucoma patients non-invasively in the clinic, long after the implant goes in.
Avisi Technologies is a clinical-stage ophthalmic medical device company building VisiPlate, an ultrathin, nanotechnology-enabled aqueous shunt that drains excess fluid from the eye to lower pressure in glaucoma patients. Spun out of the University of Pennsylvania's Y-Prize program in 2017, the company is advancing VisiPlate through the FDA-cleared SAPPHIRE pivotal trial and has raised roughly $21.7M to date, including a $10.7M Series A in February 2026.